The Efficacy of Drug-Coated Balloon for Acute Coronary Syndrome

Background. Percutaneous coronary intervention using a drug-eluting stent (DES) is a common therapeutic option for acute coronary syndrome (ACS). However, stent-associated complications, such as bleeding associated with dual antiplatelet therapy, in-stent restenosis, stent thrombosis, and neoatheros...

Full description

Saved in:
Bibliographic Details
Main Authors: Hirokazu Naganawa, Akira Ito, Shinrou Saiki, Daisuke Nishi, Shinichi Takamatsu, Yoshihisa Ito, Takeshi Suzuki
Format: Article
Language:English
Published: Wiley 2023-01-01
Series:Cardiology Research and Practice
Online Access:http://dx.doi.org/10.1155/2023/4594818
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850219706648100864
author Hirokazu Naganawa
Akira Ito
Shinrou Saiki
Daisuke Nishi
Shinichi Takamatsu
Yoshihisa Ito
Takeshi Suzuki
author_facet Hirokazu Naganawa
Akira Ito
Shinrou Saiki
Daisuke Nishi
Shinichi Takamatsu
Yoshihisa Ito
Takeshi Suzuki
author_sort Hirokazu Naganawa
collection DOAJ
description Background. Percutaneous coronary intervention using a drug-eluting stent (DES) is a common therapeutic option for acute coronary syndrome (ACS). However, stent-associated complications, such as bleeding associated with dual antiplatelet therapy, in-stent restenosis, stent thrombosis, and neoatherosclerosis, remain. Drug-coated balloons (DCBs) are expected to reduce stent-associated complications. This study aimed to assess the efficacy of DCB therapy and compare it with that of DES therapy in patients with ACS. Materials and Methods. In this single-center, retrospective, observational study, we examined all patients with ACS treated with DCB or DES between July 2014 and November 2020. Patients with left main trunk lesions were excluded. The primary outcome was a composite of major adverse cardiovascular events (MACE: cardiac death, myocardial infarction, and target lesion revascularization) at one year. Results. Three hundred and seventy-two patients were treated with DES, and 83 patients were treated with DCB. MACE occurred in 10 (12.0%) patients in the DCB group and in 50 (13.4%) patients in the DES group (P=0.73). Conclusions. DCB is a valuable and effective therapy for patients with ACS. Moreover, DCB may become an alternative therapy for DES in patients with ACS.
format Article
id doaj-art-797017f4cc914c3ca9b41ebcc0c7cc80
institution OA Journals
issn 2090-0597
language English
publishDate 2023-01-01
publisher Wiley
record_format Article
series Cardiology Research and Practice
spelling doaj-art-797017f4cc914c3ca9b41ebcc0c7cc802025-08-20T02:07:17ZengWileyCardiology Research and Practice2090-05972023-01-01202310.1155/2023/4594818The Efficacy of Drug-Coated Balloon for Acute Coronary SyndromeHirokazu Naganawa0Akira Ito1Shinrou Saiki2Daisuke Nishi3Shinichi Takamatsu4Yoshihisa Ito5Takeshi Suzuki6Department of CardiologyDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyBackground. Percutaneous coronary intervention using a drug-eluting stent (DES) is a common therapeutic option for acute coronary syndrome (ACS). However, stent-associated complications, such as bleeding associated with dual antiplatelet therapy, in-stent restenosis, stent thrombosis, and neoatherosclerosis, remain. Drug-coated balloons (DCBs) are expected to reduce stent-associated complications. This study aimed to assess the efficacy of DCB therapy and compare it with that of DES therapy in patients with ACS. Materials and Methods. In this single-center, retrospective, observational study, we examined all patients with ACS treated with DCB or DES between July 2014 and November 2020. Patients with left main trunk lesions were excluded. The primary outcome was a composite of major adverse cardiovascular events (MACE: cardiac death, myocardial infarction, and target lesion revascularization) at one year. Results. Three hundred and seventy-two patients were treated with DES, and 83 patients were treated with DCB. MACE occurred in 10 (12.0%) patients in the DCB group and in 50 (13.4%) patients in the DES group (P=0.73). Conclusions. DCB is a valuable and effective therapy for patients with ACS. Moreover, DCB may become an alternative therapy for DES in patients with ACS.http://dx.doi.org/10.1155/2023/4594818
spellingShingle Hirokazu Naganawa
Akira Ito
Shinrou Saiki
Daisuke Nishi
Shinichi Takamatsu
Yoshihisa Ito
Takeshi Suzuki
The Efficacy of Drug-Coated Balloon for Acute Coronary Syndrome
Cardiology Research and Practice
title The Efficacy of Drug-Coated Balloon for Acute Coronary Syndrome
title_full The Efficacy of Drug-Coated Balloon for Acute Coronary Syndrome
title_fullStr The Efficacy of Drug-Coated Balloon for Acute Coronary Syndrome
title_full_unstemmed The Efficacy of Drug-Coated Balloon for Acute Coronary Syndrome
title_short The Efficacy of Drug-Coated Balloon for Acute Coronary Syndrome
title_sort efficacy of drug coated balloon for acute coronary syndrome
url http://dx.doi.org/10.1155/2023/4594818
work_keys_str_mv AT hirokazunaganawa theefficacyofdrugcoatedballoonforacutecoronarysyndrome
AT akiraito theefficacyofdrugcoatedballoonforacutecoronarysyndrome
AT shinrousaiki theefficacyofdrugcoatedballoonforacutecoronarysyndrome
AT daisukenishi theefficacyofdrugcoatedballoonforacutecoronarysyndrome
AT shinichitakamatsu theefficacyofdrugcoatedballoonforacutecoronarysyndrome
AT yoshihisaito theefficacyofdrugcoatedballoonforacutecoronarysyndrome
AT takeshisuzuki theefficacyofdrugcoatedballoonforacutecoronarysyndrome
AT hirokazunaganawa efficacyofdrugcoatedballoonforacutecoronarysyndrome
AT akiraito efficacyofdrugcoatedballoonforacutecoronarysyndrome
AT shinrousaiki efficacyofdrugcoatedballoonforacutecoronarysyndrome
AT daisukenishi efficacyofdrugcoatedballoonforacutecoronarysyndrome
AT shinichitakamatsu efficacyofdrugcoatedballoonforacutecoronarysyndrome
AT yoshihisaito efficacyofdrugcoatedballoonforacutecoronarysyndrome
AT takeshisuzuki efficacyofdrugcoatedballoonforacutecoronarysyndrome